Showing results (331-340 of 352) with videos related to

Sort By:
Pageof 36
Blood Advances|March 8, 2023
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensityAlexandre Bazinet, Tapan Kadia, Nicholas J Short, et al.
Leukemia|May 19, 2021
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrationsNitin Jain, Philip Thompson, Jan Burger, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 14, 2021
Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology GroupRashmi Kanagal-Shamanna, Attilio Orazi, Robert P Hasserjian, et al.
Haematologica|December 12, 2024
Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasmsJayastu Senapati, Sanam Loghavi, Guillermo Garcia-Manero, et al.
American Journal of Hematology|March 1, 2020
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapyGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Caleb A Class, et al.
The Lancet. Haematology|November 19, 2022
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trialElias Jabbour, Nicholas J Short, Nitin Jain, et al.
Cardiology and Therapy|November 6, 2024
Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in IndiaUday M Jadhav, Saumitra Ray, T Govindan Unni, et al.
Hepatology (Baltimore, Md.)|March 3, 2020
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled TrialKeyur Patel, Stephen A Harrison, Magdy Elkhashab, et al.
Alimentary Pharmacology & Therapeutics|September 9, 2025
Prediction of Hepatocellular Carcinoma and Other Liver-Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction-Associated Steatotic Liver DiseaseLesley A Patmore, Ivana Carey, Jordan J Feld, et al.
The New England Journal of Medicine|May 30, 2019
Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, Michael Keating, Philip Thompson, et al.
Pageof 36